Aethlon Medical (NASDAQ:AEMD) Now Covered by Analysts at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a report released on Sunday. The brokerage set a “sell” rating on the medical equipment provider’s stock.

Separately, HC Wainwright decreased their target price on Aethlon Medical from $23.00 to $10.00 and set a “buy” rating for the company in a research report on Monday, March 4th.

Aethlon Medical Trading Up 0.7 %

Shares of NASDAQ:AEMD opened at $1.37 on Friday. The stock has a market cap of $3.59 million, a PE ratio of -0.27 and a beta of 1.88. The stock’s fifty day simple moving average is $1.64 and its two-hundred day simple moving average is $1.75. Aethlon Medical has a 1-year low of $1.33 and a 1-year high of $5.00.

Aethlon Medical (NASDAQ:AEMD) last released its quarterly earnings results on Wednesday, February 14th. The medical equipment provider reported ($1.37) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.14). On average, sell-side analysts forecast that Aethlon Medical will post -4.98 earnings per share for the current fiscal year.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.